---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-000542"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:12:26.310314+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# atai Life Sciences invests $50M in Beckley Psytech for 35.5% stake, adding two clinical-stage psychedelic programs

## Summary
- Total investment $50M: $40M primary issuance + $10M secondary share purchase; atai to own ~35.5% of Beckley Psytech.
- Acquires BPL-003 (intranasal 5-MeO-DMT) for Treatment Resistant Depression and Alcohol Use Disorder, and ELE-101 (IV psilocin) for MDD.
- Multiple clinical readouts expected within 12 months, including Phase 2b BPL-003 TRD data in 2H24.
- atai receives 1:1 warrant coverage at 30% premium on primary, 3 of 9 board seats, and right of first refusal/negotiation.
- Beckley Psytech remains independent; transaction closed Jan 3, 2024.

## SEC filing metadata
- accession: 0001140361-24-000542
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036124000542/0001140361-24-000542-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036124000542/ef20017595_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-000542
- JSON: https://secwatch.observer/filing/0001140361-24-000542.json
- Plain text: https://secwatch.observer/filing/0001140361-24-000542.txt

## Key facts
- M&A Transactions
  ATAI Life Sciences N.V. completed an acquisition involving Beckley Psytech Limited for $39,999,999.10 (closed 2024-01-03).
  - Action: acquisition
  - Counterparty: Beckley Psytech Limited
  - Consideration: $39,999,999.10
  - Closing: 2024-01-03
  source text: On January 3, 2024 (the “Completion Date”), atai Life Sciences N.V. (the “Company”) entered into a subscription and shareholders’ agreement with Beckley Psytech Limited, a company incorporated in England and Wales (“BPL”), and certain other shareholders of BPL as identified in such agreement (the “SSA”). Pursuant to the terms of the SSA, the Company (a) acquired 24,096,385 newly issued series C preferred shares, par value £0.0001 per share, of BPL (the “Series C Shares”) for a total purchase price of $39,999,999.10 (the “Primary Investment”);
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124000542/0001140361-24-000542-index.htm
- Material Agreements
  ATAI Life Sciences N.V. entered into Subscription and Shareholders' Agreement with Beckley Psytech Limited valued at $49,999,999.50 (effective 2024-01-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Beckley Psytech Limited
  - Value: $49,999,999.50
  - Effective: 2024-01-03
  source text: On January 3, 2024 (the “Completion Date”), atai Life Sciences N.V. (the “Company”) entered into a subscription and shareholders’ agreement with Beckley Psytech Limited, a company incorporated in England and Wales (“BPL”), and certain other shareholders of BPL as identified in such agreement (the “SSA”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036124000542/0001140361-24-000542-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.